Cervical high-risk HPV
Conditions
Interventions
Research group:Use of interferon alpha 2b suppository
Control group:Use of placebo
Sponsors
The first hospital of Jilin University
Eligibility
Sex/Gender
Female
Age
20 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. The DNA test of high-risk HPV was positive; 2. No intraepithelial tumor cells and malignant cells were found in TCT; 3. Women aged 20 to 60 years, married or having a history of sexual activity; 4. Patients without immuno deficiency and major organ disease; 5. Those who can persist in completing the treatment; 6. No other treatments are allowed during this period of treatment; 7. Voluntarily participate in the study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant, lactating women or within 6 months after delivery; 2. Cervical pathological examination combined with cervical intraepithelial neoplasia (including CIN I-III grade); 3. Patients with cervical cancer; 4. Have all sorts of vaginitis, or acute, subacute pelvic inflammatory disease; 5. Allergic constitution, or known allergy to E. coli expressed protein or other components of tested drug; 6. Chronic diseases in internal medicine, immune system diseases and other syndromes, nervous system diseases, and other researchers think that patients should not be included in this trial; 7. Have a history of serious drug abuse or alcohol abuse; 8. The patients who used intravaginal or anti HPV drugs in recent 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hr-HPVDNA clearance rate;hr-HPVDNA overall response rate; | — |
Countries
China
Contacts
Public ContactYuan Chunli
The first hospital of Jilin University
Outcome results
None listed